Stay updated with breaking news from Caamtech Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Dr. Discordia brings over 30 years of pharmaceutical industry experience to CaaMTech ISSAQUAH, Wash. - February 17, 2022 - (Newswire.com) CaaMTech, Inc. announced today that the company has appointed Robert (Bob) Discordia, Ph.D., as its Chief Scientific Officer (CSO). Dr....
The paper, co-authored by Delix Therapeutics co-founder and chief scientific officer David Olson, Ph.D., posits that the novel molecule — baptized “DLX-1” — may have the potential to produce some of the antidepressant effects of classic psychedelics without altering one’s perception or producing a mystical experience. Delix Therapeutics, a Boston-based biotech company, develops novel psychedelic-derived medicines and therapies to treat serious psychiatric and neurological conditions. “Psychedelics, like LSD and psilocybin, impact the brain in two profound ways,” Olson told ...